Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMP Therapeutics Ltd.

www.cmptherapeutics.com

Latest From CMP Therapeutics Ltd.

CMP Therapeutics Readies EU Launch With An Eye On The U.S.

CMP Therapeutics talks with large and small pharmas about distributing its micronized nasal spray, branded as Atlantic Secret. EU regulatory approval came seven years after the firm’s launch, but CEO Neil Moray Mackenzie expects much less time before a U.S. launch.

Consumer Europe

CMP Therapeutics Readies EU Launch With An Eye On The U.S.

CMP Therapeutics talks with large and small pharmas about distributing its micronized nasal spray, branded as Atlantic Secret. EU regulatory approval came seven years after the firm’s launch, but CEO Neil Moray Mackenzie expects much less time before a U.S. launch.

Consumer Europe

Respiratory Therapies: Moving Beyond Symptomatic Relief

Existing treatments for airway and lung disorders, including allergies, asthma and chronic obstructive pulmonary disease, provide widely effective symptom relief. New products in development aim to halt progression and even reverse the disorders. We profile three emerging respiratory drug developers in this issue: Pearl Therapeutics, Protectimmun and Pulmatrix.
BioPharmaceutical

CMP Therapeutics Ltd.

Chitin may be the second most common molecule on earth. It could be the source of a treatment for the common cold, too. So hope investors in CMP Therapeutics Ltd., which is developing a micronized nose-spray version of the polysaccharide chitin. The company is also using chitin as the basis for programs in novel allergy and asthma therapies, vaccine adjuvants, and nutritional products.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
  • Therapeutic Areas
  • Immune Disorders
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • CMP Therapeutics Ltd.
  • Senior Management
  • Neill M Mackenzie, PhD, CEO
    Peter Strong, PhD, CSO
  • Contact Info
  • CMP Therapeutics Ltd.
    Phone: (44) 1727 834846
    BioPark
    Broadwater Rd.
    Welwyn Garden City, AL7 3AX
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register